Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Lymphoid 1

Conditions

Recurrence 3Ovarian Neoplasms 3

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Gemcitabine 7Cyclophosphamide 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × chiauranib × Gynecologic × Clear all
NCT04921527 2024-10-18

CHIPRO

Chipscreen Biosciences, Ltd.

Phase 3 Recruiting
454 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03901118 2021-03-19

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 2 Completed
47 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03166891 2020-01-18

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
25 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡